Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 3
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. …
C3G
Novartis PharmaceuticalsNCT04817618
Phase 2
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated ki…
IgANC3GComplement-mediated Kidney Disease+2 more
ADARx Pharmaceuticals, Inc.NCT06989359